These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38491825)

  • 21. Targeted Therapy in Advanced Melanoma With Rare
    Menzer C; Menzies AM; Carlino MS; Reijers I; Groen EJ; Eigentler T; de Groot JWB; van der Veldt AAM; Johnson DB; Meiss F; Schlaak M; Schilling B; Westgeest HM; Gutzmer R; Pföhler C; Meier F; Zimmer L; Suijkerbuijk KPM; Haalck T; Thoms KM; Herbschleb K; Leichsenring J; Menzer A; Kopp-Schneider A; Long GV; Kefford R; Enk A; Blank CU; Hassel JC
    J Clin Oncol; 2019 Nov; 37(33):3142-3151. PubMed ID: 31580757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG.
    Franklin C; Mohr P; Bluhm L; Grimmelmann I; Gutzmer R; Meier F; Garzarolli M; Weichenthal M; Pfoehler C; Herbst R; Terheyden P; Utikal J; Ulrich J; Debus D; Haferkamp S; Kaatz M; Forschner A; Leiter U; Nashan D; Kreuter A; Sachse M; Welzel J; Heinzerling L; Meiss F; Weishaupt C; Gambichler T; Weyandt G; Dippel E; Schatton K; Celik E; Trommer M; Helfrich I; Roesch A; Zimmer L; Livingstone E; Schadendorf D; Horn S; Ugurel S
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
    Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
    Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
    Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
    Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
    Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
    Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
    Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
    Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
    Moser JC; Chen D; Hu-Lieskovan S; Grossmann KF; Patel S; Colonna SV; Ying J; Hyngstrom JR
    Cancer Med; 2019 Dec; 8(18):7637-7643. PubMed ID: 31677253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.
    Amini-Adle M; Khanafer N; Le-Bouar M; Duru G; Dalle S; Thomas L
    BMC Cancer; 2018 Jul; 18(1):705. PubMed ID: 29970025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
    Devji T; Levine O; Neupane B; Beyene J; Xie F
    JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
    Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
    Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis.
    Petrelli F; Ardito R; Merelli B; Lonati V; Cabiddu M; Seghezzi S; Barni S; Ghidini A
    Melanoma Res; 2019 Feb; 29(1):1-12. PubMed ID: 30308577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma.
    Guida M; Bartolomeo N; Quaresmini D; Quaglino P; Madonna G; Pigozzo J; Di Giacomo AM; Minisini AM; Tucci M; Spagnolo F; Occelli M; Ridolfi L; Queirolo P; De Risi I; Valente M; Sciacovelli AM; Chiarion Sileni V; Ascierto PA; Stigliano L; Strippoli S
    J Transl Med; 2022 Apr; 20(1):159. PubMed ID: 35382857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
    Harding JJ; Catalanotti F; Munhoz RR; Cheng DT; Yaqubie A; Kelly N; McDermott GC; Kersellius R; Merghoub T; Lacouture ME; Carvajal RD; Panageas KS; Berger MF; Rosen N; Solit DB; Chapman PB
    Oncologist; 2015 Jul; 20(7):789-97. PubMed ID: 25956405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
    Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients.
    Ferrucci PF; Lens M; Cocorocchio E
    Curr Oncol Rep; 2021 Nov; 23(12):138. PubMed ID: 34735635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.
    Saiag P; Robert C; Grob JJ; Mortier L; Dereure O; Lebbe C; Mansard S; Grange F; Neidhardt EM; Lesimple T; Machet L; Bedane C; Maillard H; Dalac-Rat S; Nardin C; Szenik A; Denden A; Dutriaux C
    Eur J Cancer; 2021 Sep; 154():57-65. PubMed ID: 34243078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
    Ribas A; Lawrence D; Atkinson V; Agarwal S; Miller WH; Carlino MS; Fisher R; Long GV; Hodi FS; Tsoi J; Grasso CS; Mookerjee B; Zhao Q; Ghori R; Moreno BH; Ibrahim N; Hamid O
    Nat Med; 2019 Jun; 25(6):936-940. PubMed ID: 31171879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.
    Ghate S; Ionescu-Ittu R; Burne R; Ndife B; Laliberté F; Nakasato A; Duh MS
    Melanoma Res; 2019 Jun; 29(3):301-310. PubMed ID: 30247203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.
    Hauschild A; Ascierto PA; Schadendorf D; Grob JJ; Ribas A; Kiecker F; Dutriaux C; Demidov LV; Lebbé C; Rutkowski P; Blank CU; Gutzmer R; Millward M; Kefford R; Haas T; D'Amelio A; Gasal E; Mookerjee B; Chapman PB
    Eur J Cancer; 2020 Jan; 125():114-120. PubMed ID: 31864178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma.
    Kartolo A; Deluce J; Hopman WM; Liu L; Baetz T; Ernst S; Lenehan JG
    Curr Oncol; 2022 Mar; 29(3):1501-1513. PubMed ID: 35323326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.